Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials

Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chro...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Obes Metab
Asıl Yazarlar: Tuttle, Katherine R., McKinney, T. Dwight, Davidson, Jaime A., Anglin, Greg, Harper, Kristine D., Botros, Fady T.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2016
Konular:
Brief Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5347883/
https://ncbi.nlm.nih.gov/pubmed/27766728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12816
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller